Abstract 22P
Background
Although the use of immunocheckpoint inhibitors (ICIs) in cancer treatment has become widespread, the factors predicting the response to these treatments have not yet entered our clinical practice. Considering that the progression under ICIs is especially in the first 3-6 months, there is a need for biomarkers to help us determine which patients do not benefit from these treatments. It is important to detect an easy and inexpensive biomarker in order to be widespread in our clinical practice. In our study, we aimed to examine the relationship between mean platelet volume/lymphocyte ratio, which can be evaluated by hemogram test, and overall survival in cancer patients treated with nivolumab.
Methods
A total of 131 adult metastatic cancer patients treated with nivolumab for malignant melanoma (MM), renal cell carcinom (RCC), non-small cell lung cancer (NSCLC) and head and neck (HNC) cancer patients were included. Baseline demographics, ECOG performance status, type of tumors, and baseline blood count parameters were recorded. Possible predisposing factors were evaluated with univariate and multivariate analyses.
Results
The median age was 59.87 ± 11.97 years, and the median follow-up was 20.20 (IQR 12.80-27.60) months. Renal cell carcinoma (43.5%) and melanoma (25.9%) were most common diagnoses. Patients with ECOG 0-1 (mOS: 20.60 months (95% CI: 14.94-25.29) vs 5.24 months (95% CI: 0-16.42), p<0.001), LDH levels within the normal range (mOS: 24.54 months (95% CI: 14.13-34.96) vs 13.10 months (95% CI: 4.49-21.72), p=0.038) and low MPVLR (mOS: 33.70 months (95% CI: 25.99-41.42) vs 11.07 months (95% CI: 6.89-15.24), p<0.001) had a longer median overall survival. In multivariate Cox regression analysis, high MPV/Lymphocyte ratio, ECOG score 2-3 and high LDH level were associated with shorter overall survival time (p<0.001, p=0.001 and p=0.046 respectively).
Conclusions
In this study, we determined that MPVLR could be a new biomarker predicting response to nivolumab treatment.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.